Apparent mineralocorticoid excess syndromes

J Endocrinol Invest. 1995 Jul-Aug;18(7):518-32. doi: 10.1007/BF03349763.

Abstract

Apparent mineralocorticoid excess (AME) is a syndrome attributable to congenital deficiency of the enzyme 11 beta-dehydrogenase (11 beta-OHSD) which converts active glucocorticoid cortisol to inactive cortisone. When 11 beta-OHSD activity is impaired, cortisol acts as a potent mineralocorticoid and causes hypertension and hypokalemia with a suppression of the renin-angiotensin-aldosterone system. The increased ratio of urinary cortisol/cortisone metabolites and a prolonged half-life of cortisol are useful for the diagnosis. Dexamethasone and/or potassium sparing diuretics have been used for medication of AME. Licorice ingestion induces a mineralocorticoid excess state, and it seems that this is the result of acquired inhibition of 11 beta-DH by glycyrrhetinic acid. The existence of a second 11 beta-OHSD isoform has been suggested strongly for a long time, and recently, a human 11 beta-OHSD 2 cDNA has been isolated. It appears that 11 beta-OHSD 2 conveys specificity upon the renal MR, and a defect in its activity seems likely to account for the phenotype of AME.

Publication types

  • Review

MeSH terms

  • 11-beta-Hydroxysteroid Dehydrogenases
  • Animals
  • Humans
  • Hydrocortisone / metabolism*
  • Hydroxysteroid Dehydrogenases / deficiency*
  • Hydroxysteroid Dehydrogenases / genetics
  • Hydroxysteroid Dehydrogenases / physiology
  • Hypertension / diagnosis
  • Hypertension / drug therapy
  • Hypertension / etiology*
  • Hypokalemia / diagnosis
  • Hypokalemia / drug therapy
  • Hypokalemia / etiology*
  • Mineralocorticoids / biosynthesis
  • Mineralocorticoids / metabolism*
  • Mineralocorticoids / physiology
  • Syndrome

Substances

  • Mineralocorticoids
  • Hydroxysteroid Dehydrogenases
  • 11-beta-Hydroxysteroid Dehydrogenases
  • Hydrocortisone